Diagnostic accuracy, operational feasibility, and cost considerations of Truenat MTB Plus and Xpert MTB/RIF Ultra for pulmonary tuberculosis
Open Access
- 8 July 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0341988
Abstract
Background: Tuberculosis (TB) remains a major global health challenge, necessitating rapid and accurate diagnostic tools. The World Health Organization (WHO) endorses nucleic acid amplification tests (NAATs) like Truenat MTB Plus and Xpert MTB/RIF Ultra. While both are widely implemented, direct comparisons integrating diagnostic accuracy with operational and cost considerations across real-world settings are limited. This study aimed to compare the diagnostic accuracy of Truenat MTB Plus and Xpert MTB/RIF Ultra for the detection of Mycobacterium tuberculosis (MTB) and rifampicin resistance (RIF-R) among presumptive pulmonary TB patients in India, while also assessing their operational feasibility and cost-related parameters. Methods: This prospective diagnostic accuracy study was conducted at New Delhi Tuberculosis Centre, in New Delhi, India, enrolling 664 presumptive pulmonary TB patients. Paired sputum specimens were tested using Truenat MTB Plus/MTB-RIF and Xpert MTB/RIF Ultra. Mycobacterial culture was used as the primary reference standard for MTB detection, and phenotypic drug susceptibility testing (pDST) was used for RIF-R detection. Sensitivity, specificity, and overall accuracy were calculated, and operational parameters, including invalid/indeterminate rates and cost per test, were recorded. Results: The overall prevalence of culture-confirmed TB was 14.8% (98/664), with a RIF-R prevalence of 7.1% (7/98). Compared with culture, Xpert MTB/RIF Ultra demonstrated a sensitivity of 97.9% (95% CI: 95.2–100%) and a specificity of 95.5% (95% CI: 93.7–97.3%). Truenat MTB Plus showed a sensitivity of 92.5% (95% CI: 85.1–96.6%) and a specificity of 90.1% (95% CI: 86.8–92.6%). For RIF-R detection, Xpert Ultra had a sensitivity of 83.3% and a specificity of 100%, compared to Truenat MTB-RIF’s sensitivity of 75.0% and specificity of 100%. Operationally, Truenat had a significantly higher rate of invalid results (5.9% vs 0%) and RIF indeterminate results (46.5% vs 13.2%) compared to Xpert Ultra, resulting in an increased need for repeat testing. The cost per test was lower for Truenat (approximately INR 800 for MTB Plus) compared to Xpert MTB/RIF Ultra (approximately INR 1800). Conclusion: Both Truenat MTB Plus and Xpert MTB/RIF Ultra demonstrated excellent diagnostic accuracy for TB detection. Xpert Ultra showed superior accuracy and lower indeterminate rates, while Truenat offers substantial operational and cost advantages for decentralized deployment; however, higher rates of invalid and indeterminate results may increase operational burden due to repeat testing. These findings support a tiered diagnostic approach, leveraging the strengths of both platforms to expand molecular testing access and accelerate progress toward global TB elimination goals.Keywords
This publication has 9 references indexed in Scilit:
- Diagnostic accuracy of Truenat MTB Ultima on sputum for pulmonary TB diagnosis in an HIV-endemic settingClinical Microbiology and Infection, 2025
- Accuracy of Truenat™ MTB Plus for the diagnosis of pulmonary TBIJTLD OPEN, 2025
- Multi-centric evaluation of Truenat MTB and MTB-RIF Dx assays for diagnosis of extrapulmonary tuberculosisScientific Reports, 2024
- Diagnostic Accuracy of the Truenat MTB Plus Assay and Comparison with the Xpert MTB/RIF Assay to Detect Tuberculosis among Hospital Outpatients in CameroonJournal of Clinical Microbiology, 2022
- Diagnostic accuracy of Truenat Tuberculosis and Rifampicin-Resistance assays in Addis Ababa, EthiopiaPLOS ONE, 2021
- WHO consolidated guidelines on tuberculosis: Module 3: diagnosis – rapid diagnostics for tuberculosis detection2021
- Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy studyThe Lancet Infectious Diseases, 2018
- Evaluation of the Indian TrueNAT micro RT-PCR device with GeneXpert for case detection of pulmonary tuberculosisInternational Journal of Mycobacteriology, 2014
- Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation studyThe Lancet, 2011